About

Point of Care (PoC) medical diagnostics is a $ multi-billion global market, and is forecast to grow at an average rate of over 10% per annum to 2014, at which point it will be worth in excess of $22 billion.

Driven by patient need for self monitoring and healthcare cost savings, hand-held devices or readers offering rapid diagnostic test results are fast replacing often slow and expensive laboratory analysis across a range of chronic illnesses and medical conditions that require either regular monitoring or simple “yes/no” results.

Bio-AMD is in various stages of development of fully patented technology platforms that can be adapted to provide semi-quantitative and quantitative measurement in PoC devices, using both existing lateral flow and nano/micro-fluidic strips to detect a wide range of various medical conditions.

Bio-AMD comprises a small team with deep expertise and know-how in the application of magnetism and electronics into immunoassay testing, and strong commercial experience of the PoC market. Based at the Daresbury Science and Innovation Campus in the United Kingdom, Bio-AMD is well positioned to become the leading innovator in the field of reader technology development.